STOCK TITAN

Fennec Pharmaceuticals (FENC) 10-Q Filings

FENC NASDAQ

Here are the 10-Q quarterly reports from Fennec Pharmaceuticals Inc. (FENC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.

Rhea-AI Summary

Fennec Pharmaceuticals Inc. (FENC) reported third-quarter 2026 revenue of $19.608 million, including $19.425 million in net PEDMARK sales, versus $12.462 million in third-quarter 2025. Net income was $4.640 million, versus a $638,000 loss; diluted earnings per share were $0.12 versus a $0.02 loss. For the first nine months, revenue was $52.590 million and net income was $6.814 million, compared with $30.865 million in revenue and a $4.954 million loss in 2025.

Cash and cash equivalents were $48.684 million at September 30, 2026. Nine-month operating cash flow was $9.111 million, versus $6.511 million used in 2025. Fennec believes existing cash and expected operating revenues will be sufficient to fund its operating plan for at least the next twelve months from issuance of the statements.

In the open-label, single-arm Japanese STS-J01 study, American Speech-Language-Hearing Association-defined hearing loss occurred in 6 of 25 patients (24.0%), versus a 56.4% historical benchmark (p=0.001). Objective tumor responses occurred in 23 of 24 evaluable patients (95.8%), and no serious adverse event was attributed to PEDMARK. Fennec is pursuing Japanese registration and evaluating partnering or licensing opportunities; discussions with potential partners and regulators are ongoing.

Rhea-AI Summary

Fennec Pharmaceuticals reported strong growth and a shift to profitability driven by commercialization of PEDMARK®. For the quarter ended June 30, 2026, total revenue was $17.9 million, up from $9.7 million a year earlier, including PEDMARK net product sales of $17.2 million and $0.7 million of other revenue from its PEDMARQSI® license with Norgine.

Quarterly income from operations was $1.7 million versus a loss of $2.7 million, and net income was $2.0 million versus a net loss of $3.2 million. For the first six months of 2026, revenue reached $33.0 million, with net income of $2.2 million compared to a $4.3 million loss in 2025, and operating cash flow improved to $2.4 million.

Growth was accompanied by a sharp increase in selling and marketing expense to $10.7 million in the quarter, reflecting continued U.S. commercialization and support for international expansion through Norgine. Fennec ended June 30, 2026 with $41.2 million in cash and cash equivalents and $42.4 million of stockholders’ equity, and believes existing cash plus expected revenues will fund operations for at least the next twelve months.

Rhea-AI Summary

Fennec Pharmaceuticals Inc. reported strong quarterly growth as PEDMARK product sales, net, rose to $15.1 million for the three months ended March 31, 2026, up from $8.8 million a year earlier. Higher revenue helped the company swing from a net loss of $1.2 million in 2025 to net income of $0.2 million and positive operating cash flow of $2.4 million. Cash and cash equivalents increased to $40.2 million, with working capital of $57.3 million, and management believes this is sufficient to fund operations for at least twelve months. Fennec also highlighted its ex‑U.S. PEDMARQSI® license with Norgine, which included an upfront payment of about $43 million and potential milestones up to roughly $230 million, and a settlement with Cipla that delays U.S. generic sodium thiosulfate entry until September 1, 2033 under agreed terms.

Rhea-AI Summary

Fennec Pharmaceuticals (FENC) reported Q3 2025 results with PEDMARK net product sales of $12,462 (up from $6,974 a year ago). For the nine months, net product sales were $30,865 versus $21,655 in 2024. Q3 operating loss was $(189) and net loss was $(638), or $(0.02) per share.

Cash and cash equivalents were $21,947, total assets $49,261, and total liabilities $53,753, resulting in a stockholders’ deficit of $(4,492). The balance sheet reflects a term loan of $18,206 and accrued PIK interest of $1,271 under the Petrichor notes; following December 2024 redemptions, $19,477 remained outstanding as of September 30, 2025. Operating cash flow for the nine months was $(6,511); financing cash flow was $1,824.

The company continues to account for its 2024 Norgine license—approximately $43,000 was received upfront, with $24,561 recorded as long‑term contract liability. As of November 10, 2025, common shares outstanding were 28,116,829.